Smith & Nephew 3Q Sales Falls to $952M

Smith & Nephew has reported third-quarter sales of $952 million, down from the $1.03 billion reported last year, according to a Bloomberg Businessweek report.

Advertisement

The sales decline was attributed to revenue loss from its biologics and clinical therapies business line, which spun off and was branded Bioventus. Broken out by business line, sales from Smith & Nephew’s knee products fell 1 percent, while its sports medicine products saw an 8 percent hike.

More Articles on Orthopedic Devices:

NeuroMetrix Signs Distribution Agreement for Pain Management Device

10 New Spine Device Launches

ConforMIS Moves Corporate Headquarters

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Watch On-Demand Webinar

ASC development + private equity: How to build value from day one

Presenters: Andrew HrankaWendy Bruno Thomson, MBA, LHARichard Romero, CVA, ABV, FHFMA, PAHM

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.